Compare Dominion Energy Inc (D) vs Summit Therapeutics Inc (SMMT) Price & Performance

Dominion Energy (D) trades at $67.81, up 1.0% today, with a consensus price target of $70.43 offering modest upside potential. The stock shows strong fundamental performance with Q2 2026 EPS beating estimates at $0.79 versus $0.681 expected, marking the third consecutive quarterly beat. Technical indicators signal bearish momentum with the current price near key support at $67, while institutional sentiment remains mixed with 34% buy ratings versus 59% hold.

The utility's outlook is supported by growing data center demand and reaffirmed 2026 guidance, though rising operating costs and a potential NextEra merger create uncertainty. Investment appeal centers on stable dividend payments and infrastructure growth, balanced against debt levels above 40% of assets and regulatory exposure.

Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.

The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.